Physician profile
Sara Huff
NPI 1386147197
$6,756.26
in general payments reported to CMS, 2019-2025
30 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2021: $360 · 2022: $728 · 2023: $2,717 · 2024: $1,442 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,954 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.07 |
| Education | $300.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.41 | 2022-2025 | |
| Janssen Biotech, INC. | $797.96 | 2022-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $685.59 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $475.12 | 2023-2025 | Zoryve |
| Incyte Corporation | $393.43 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $327.12 | 2022-2025 | Absorica Ld, Winlevi, Blu-U |
| Stemline Therapeutics INC. | $270.30 | 2019-2021 | |
| Lilly USA, LLC | $236.91 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $229.49 | 2022-2025 | |
| Galderma Laboratories, L.P. | $220.31 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $204.22 | 2022-2024 | Otezla |
| Genzyme Corporation | $202.65 | 2022-2025 | |
| Dermavant Sciences, INC. | $192.25 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $188.04 | 2022-2025 | Sotyktu |
| Mallinckrodt Enterprises LLC | $182.93 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $177.81 | 2023-2024 | |
| Journey Medical Corporation | $145.07 | 2022-2025 | |
| Ucb, INC. | $136.77 | 2023-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $119.54 | 2023-2024 | Adbry |
| Biofrontera INC. | $108.21 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $101.88 | 2022 | |
| Mayne Pharma Commercial LLC | $79.86 | 2022-2024 | |
| Organogenesis INC. | $79.58 | 2023-2025 | Puraply, Affinity |
| Strata Skin Sciences, INC. | $77.14 | 2023 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.80 | 2023-2025 | Spevigo |
| Almirall LLC | $39.91 | 2023 | Klisyri |
| Verrica Pharmaceuticals INC. | $38.80 | 2024 | Ycanth |
| Krystal Biotech INC | $25.87 | 2024 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.16 | 2024 | Cabtreo |
| Kyowa Kirin, INC. | $18.13 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.